Interest In Korean Biotech IPOs Dips Amid Year-End Rush
This article was originally published in PharmAsia News
Bioventures seeking IPOs in the South Korean stock market are having a tough time due to waning interest from investors. A surge in such offerings this year, coupled with the usual IPO rush seen at the end of each year, have resulted in several biotech companies withdrawing plans or raising funds short of initial targets.
You may also be interested in...
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Korean venture Helixmith faces another setback following a missed Phase III endpoint for its plasmid DNA neuropathy candidate, with its shares plunging after it warned of a possible delay in a planned rights offering, amid concerns from minority shareholders over other investment losses.